Skip to main content
Premium Trial:

Request an Annual Quote

Personalis Prices $150M Public Stock Offering

NEW YORK – Personalis said Wednesday that it has priced a public offering of 3,950,000 shares of its common stock at $38 per share.

The Menlo Park, California-based firm expects gross proceeds from the offering to be about $150 million. It also is granting underwriters a 30-day option to purchase up to an additional 592,500 shares under the same terms and conditions.

Morgan Stanley, BofA Securities, Citigroup and Cowen are acting as joint book-running managers. BTIG is acting as co-manager.

Personalis, which has commercialized a suite of next-generation sequencing services for population genomics, cancer research, and diagnostics, said it would use proceeds from the offering for working capital and general corporate purposes.

In Wednesday morning trade on the Nasdaq, shares of Personalis were down around 10 percent at $38.43.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.